These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 8178557)

  • 1. Multiple effects of CD4 CDR3-related peptide derivatives showing anti-HIV-1 activity on HIV-1 gp120 functions.
    Ohki K; Kimura T; Jones IM; Morita F; Ikuta K
    Vaccine; 1994 Mar; 12(4):343-50. PubMed ID: 8178557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies to a CD4 peptide derivative which includes the region corresponding to an immunoglobulin CDR3: evidence of the involvement of pre-CDR3-related region in HIV-1 and host cell interaction.
    Ohki K; Kimura T; Ohmura K; Morikawa Y; Jones IM; Azuma I; Ikuta K
    Mol Immunol; 1992 Nov; 29(11):1391-400. PubMed ID: 1406723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding.
    Harrop HA; Coombe DR; Rider CC
    AIDS; 1994 Feb; 8(2):183-92. PubMed ID: 8043225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein.
    Thali M; Furman C; Wahren B; Posner M; Ho DD; Robinson J; Sodroski J
    J Acquir Immune Defic Syndr (1988); 1992; 5(6):591-9. PubMed ID: 1588493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
    Gram GJ; Hemming A; Bolmstedt A; Jansson B; Olofsson S; Akerblom L; Nielsen JO; Hansen JE
    Arch Virol; 1994; 139(3-4):253-61. PubMed ID: 7832633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125.
    Sourial S; Nilsson C; Wärnmark A; Achour A; Harris RA
    Curr HIV Res; 2006 Apr; 4(2):229-37. PubMed ID: 16611061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion.
    Broder CC; Berger EA
    J Virol; 1993 Feb; 67(2):913-26. PubMed ID: 8419649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.
    Weinberg J; Liao HX; Torres JV; Matthews TJ; Robinson J; Haynes BF
    AIDS Res Hum Retroviruses; 1997 May; 13(8):657-64. PubMed ID: 9168234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion.
    Truneh A; Buck D; Cassatt DR; Juszczak R; Kassis S; Ryu SE; Healey D; Sweet R; Sattentau Q
    J Biol Chem; 1991 Mar; 266(9):5942-8. PubMed ID: 1706342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
    Callahan LN; Phelan M; Mallinson M; Norcross MA
    J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
    Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
    Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
    Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
    PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1).
    Neurath AR; Strick N; Jiang S
    Virology; 1992 May; 188(1):1-13. PubMed ID: 1373549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
    Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
    Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.